Skip to main content
Equibles

BNP PARIBAS ARBITRAGE, SA

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 1166588 NEW YORK, NY
Back to SLS Full portfolio

Position in SLS

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$15,823,044
+$15,624,167 QoQ
Shares Held
1,072,022
+2180.1% QoQ
Ownership
0.531%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#14
of 192 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$154,242
PutShares
10,450

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

BNP PARIBAS ARBITRAGE, SA holds $3,331,911,027 across 414 Biotechnology names. SLS ranks #51 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 MRNA
Moderna, Inc.
 4,377,120 $306,529,713
2 REGN
Regeneron Pharmaceuticals, Inc.
 399,847 $249,320,598
3 ARGX
Argenx SE
 157,958 $146,548,693
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 262,258 $130,271,416
5 BNTX
BioNTech SE
 1,319,517 $122,781,056
6 RVMD
Revolution Medicines, Inc.
 552,710 $103,511,528
7 ORKA
Oruka Therapeutics, Inc.
 1,079,015 $102,689,857
8 BBIO
BridgeBio Pharma, Inc.
 1,155,442 $86,057,320

All Filings in SLS

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $15,823,044 1,072,022
2026-06-30 $154,242 10,450
2026-03-31 $198,877 47,016
2025-12-31 $101,179 26,838
2025-09-30 $31,755 19,724
2025-06-30 $22,830 10,425